November 11, 2026·48 min read

Hims & Hers Health, Inc. (HIMS), Financial Analysis

Insights derived from analysing SEC filings. Independent analysis, not a publication of the SEC.

Revenue Q3 2026
$890m
+48.6% year on year (Q3 2025 $599m)
Cost of revenue and operating expenses Q3 2026
$957m
+62.9% year on year (Q3 2025 $587m)
Operating margin Q3 2026
(7.4%)
(9.4 pts) year on year (Q3 2025 2.0%)
Key findings
  • Revenue +49% to $890.4m in Q3 2026; cost of revenue and operating expenses +62.9% to $956.5m. US revenue $657.1m, +21%; Rest of the World $233.3m, +321%, with Eucalyptus about 15% of revenue (10-Q). GAAP operating margin (7.4)% against 2.0%; net loss $33.0m against net income $15.8m.
  • Gross margin 57% against 74% a year earlier (exact 57.2% against 73.8%). The 10-Q cites product and packaging costs +176% and shipping +64%, shorter shipping cadences and higher fulfillment costs in weight loss, and growth of the international business and new offerings; it expects gross margin to stay below prior periods in the near term.
  • Subscribers 2.788m, +13% year on year and about 103,000 fewer than the 2.891m of Q2 2026. Monthly revenue per average subscriber $105 against $81; the 2026 definition includes one time purchasers. Marketing fell to 28% of revenue from 39%.
  • Adjusted EBITDA (non GAAP) $82.4m, a 9.3% margin, against $78.4m. Hims & Hers changed the definition three times: Q2 2025 (payroll tax on stock compensation), Q1 2026 (restructuring) and Q3 2026 (FX gains and losses, prior periods not recast). FY2026 guidance moved in four steps; the latest is revenue $3.13bn to $3.15bn and adjusted EBITDA $257m to $277m, against $300m to $375m in February.
  • Balance sheet at 30 Sep 2026: cash and short term investments $712.2m against $1.40bn of convertible notes and $563.1m of deferred Eucalyptus payments. 9M 2026 operating cash flow of $118.8m includes $433.3m from receivables sold to JPMorgan. An FTC lawsuit (about $60m accrued), an SEC investigation and a DOJ referral are open; Dr. Andrew Huberman joined the board with paid advisory and podcast agreements.
  • Shares closed at $19.13 on 10 Nov 2026, 16.6% below the $22.94 close of 6 Nov 2026; results were released on 9 Nov 2026, at 1.8x TTM EV/Sales (GAAP EBITDA is negative). Model price in three years on an EV/Sales basis: base $16.97, (11%); best $57.47, +200%; worst $7.28, (62%).

Figures are read from the Forms 10-K for FY2022, FY2023, FY2024 and FY2025, the Forms 10-Q for Q1 to Q3 2026 (Q3 2026 10-Q filed on 9 Nov 2026), the Forms 8-K with all their exhibits, incl. the quarterly earnings releases (Ex 99.1) and the shareholder letters (Ex 99.2) for Q4 2024 and Q4 2025, which carry the CFO commentary and guidance (Hims & Hers files no separate CFO commentary document and moved to an annual shareholder letter in 2026), the Form 8-K of 9 Nov 2026 on the board appointment, the Forms 8-K on the change of principal accounting officer, the 2026 proxy statement, the Form 8-K Item 5.07 vote results of the annual meeting and Forms 4, together with the filings of Teladoc, LifeMD, GoodRx, WW International, Novo Nordisk (Form 6-K) and Eli Lilly used in chapters 2 to 4 and 8. Accession numbers for every filing used appear in the Sources appendix. Share price $19.13 is the close of 10 Nov 2026.

1 Revenue & Business Model

  • Storyline: revenue grew 49% in Q3 2026 on acquisitions outside the US and a 21% rise in US revenue, while gross margin fell to 57%, subscribers fell by about 103,000 on Q2 2026 and adjusted EBITDA guidance for FY2026 was cut for the third time. Chapters 2 to 4 follow the revenue drivers: weight loss after the move from compounded semaglutide to branded GLP‑1 products; sexual health, dermatology and the subscriber base; and international and new specialties.
  • Hims & Hers reports one operating segment and files no revenue by specialty. The filed proxies used in this report are United States and Rest of the World revenue (by selling legal entity), subscribers, monthly revenue per average subscriber, the Hers share of US revenue and the threshold disclosures in Table 1.2. The FY2025 10-K lists sexual health, hair loss, hormone health, weight loss, dermatology, mental health and lab testing, with over 50 million telehealth consultations since founding.
  • Revenue FY2021 $271.9m to FY2025 $2.35bn, a 71.4% CAGR; TTM Q3 2026 $2.87bn. Online revenue was $2.31bn and wholesale revenue $36.2m in FY2025; the split is not reported in 2026.
  • Rest of the World revenue $233.3m in Q3 2026, 26.2% of revenue against 9.3%: Zava (UK, Germany, Ireland, France, Spain) from Jul 2025, Medici (Canada) from Nov 2025 and Eucalyptus (Australia, UK, Germany, Ireland, Canada, Japan) from 1 Jun 2026. Zava was under 5% of FY2025 revenue (10-K Item 9A) and is not reported separately.
  • Operations: two licensed 503A pharmacies, two UK GPhC licensed pharmacies, a 503B outsourcing facility, a peptide manufacturing facility acquired in Feb 2025 and a lab testing facility (10-K FY2025).
Figure 1.1 Revenue and operating margin, FY2021 to TTM Q3 2026
Figure 1.2 Revenue by region (selling legal entity), share
Table 1.1 Revenue, regions, subscribers and margins, last five quarters
LineQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue ($m)599.0617.8608.1753.2890.4
Revenue growth year on year (%)n/an/a3.838.348.6
United States revenue ($m)543.5554.1529.9621.8657.1
Rest of the World revenue ($m)55.563.778.2131.4233.3
Rest of the World share of revenue (%)9.310.312.917.426.2
Gross margin (%)73.871.965.363.857.2
Subscribers, end of quarter (thousands)2,4712,5112,5842,8912,788
Net subscriber additions (thousands)324073307(103)
Monthly revenue per average subscriber ($)81838092105
Adjusted EBITDA, non GAAP ($m)78.466.344.360.382.4
Net income (loss) ($m)15.820.6(92.1)(86.3)(33.0)
Q4 2025 equals FY2025 less 9M 2025. Net additions use the prior quarter end. Monthly revenue per average subscriber uses total revenue in 2026 and includes one time purchasers (8-K Ex 99.1). Growth for Q3 and Q4 2025 is not shown as 2024 quarterly comparatives were not collected.
Table 1.2 Revenue disclosures by specialty and brand, as filed
PeriodDisclosureSource
FY2024Revenue excluding the GLP‑1 offering $1.2bn against almost $1.5bn in total (rounded as filed)8-K Ex 99.2, Q4 2024 letter
FY2025 outlookAt least $725m from weight loss offerings (oral, liraglutide, personalized semaglutide); no FY2025 actual filed8-K Ex 99.2, Q4 2024 letter
FY2025Weight Loss, Men's Dermatology, Sexual Health and Women's Dermatology each above $100m of annual revenue; Hers brand approaching $1bn; Hims revenue up more than 30%, Hers more than 100%8-K Ex 99.2, Q4 2025 letter
FY2025 and Q1 to Q3 2026A majority of FY2025 revenue and of US revenue in each 2026 quarter came from offerings other than GLP‑1Q4 2025 letter; 10-Q MD&A
Q1 2025 to Q3 2026Hers share of US revenue about 40%, 35%, 40% (Q1 to Q3 2025), about 40% (Q1 2026), over 40% (Q2 2026) and about 45% (Q3 2026)10-Q MD&A
Q3 2026Eucalyptus about 15% of revenue (about 10% of 9M 2026 revenue); Zava not reported separately10-Q Q3 2026, Note 3
Hims & Hers files no revenue in dollars by specialty; these are the only filed figures and thresholds.

2 Weight Loss: From Compounded Semaglutide to Branded GLP‑1 Memberships

  • No weight loss revenue is filed; US revenue is the closest proxy. US revenue $657.1m in Q3 2026, +21%, after (8%) in Q1 2026 and +16% in Q2 2026 (8-K Ex 99.1). FY2024 revenue excluding the GLP‑1 offering was $1.2bn of almost $1.5bn, and the FY2025 outlook was at least $725m from weight loss offerings (Q4 2024 letter); no actual FY2025 weight loss figure was filed.
  • March 2026 shift (8-K of 11 Mar 2026): US weight loss moved to FDA approved GLP‑1s, with Ozempic and Wegovy pills and injections from Novo Nordisk on the platform; compounded GLP‑1 is no longer advertised and is offered on a limited scale. Weight loss memberships launched at the end of Mar 2026. Restructuring $41.9m in 9M 2026, incl. $28.5m of inventory write downs.
  • Margin effect (10-Q): shorter shipping cadences and higher fulfillment costs in weight loss, international growth and acquisitions lowered gross margin to 57.2% from 73.8%; receivables rose to $427.8m at 30 Sep 2026 from $32.1m at 31 Dec 2025, mainly manufacturer discount and rebate receivables on branded GLP‑1 inventory.
  • Regulation: the FDA resolved the semaglutide shortage on 21 Feb 2025, limiting 503B compounding; in Feb 2026 an FDA statement on GLP‑1 ingredients for mass marketed compounded drugs named Hims & Hers and HHS referred the company to the DOJ (10-K FY2025).

How the weight loss market is changing

  • Branded supply and self pay (Novo Nordisk 6-K, 4 Nov 2026): about 4.1m US Wegovy injectable prescriptions in Q3 2026, about 35% through the self pay channel via retail and telehealth incl. NovoCare; the Wegovy pill launched in the US on 5 Jan 2026 at self pay prices of $149 to $299 a month by dose; Novo's own Wegovy self pay subscription program had about 55,000 active subscriptions.
  • Market growth: Novo reports global branded obesity market volume growth of 70% (moving annual total, Aug 2026) and obesity care sales of DKK 26.15bn, +22% at constant exchange rates; Lilly Zepbound revenue $5.35bn, +49.2%, and Mounjaro $10.72bn, +64.6% (Lilly 10-Q).
  • Coverage: Medicare Part D coverage for obesity medicines through a bridge program started on 1 Jul 2026 (Novo 6-K).
  • Program peers: WW International revenue $152.9m in Q3 2026, (11.2%); LifeMD revenue $47.3m in Q2 2026, (3.5%) as filed and under correction.
Figure 2.1 US revenue and gross margin by quarter
Figure 2.2 Weight loss revenue growth by filer
Table 2.1 Weight loss revenue lines compared
CompanyLinePeriodDetailRevenueGrowth (%)Op. margin (%)
Hims & HersUS revenue (no weight loss line filed)Q3 2026gross margin 57%; branded GLP‑1 since Mar 2026$657.1m20.9(8.1)
Eli LillyZepbound revenueQ3 2026Mounjaro $10.72bn (+64.6%); Mounjaro, Zepbound and Foundayo 66.6% of revenue$5.35bn49.240.3
Novo NordiskWegovy pill salesQ3 2026Wegovy injectable DKK 20.41bn (2% lower, CER); obesity care DKK 26.15bn, +22%DKK 5.39bnn/a29.1
WW InternationalRevenueQ3 2026net income $15.1m; long term debt $424.0m$152.9m(11.2)23.9
LifeMDRevenue (as filed, under correction)Q2 2026NT 10-Q of 9 Nov 2026 cites revenue over recognized 2024 to Q2 2026$47.3m(3.5)(15.1)
GoodRxPharma Direct revenue (preliminary restated)Q2 2026restated from $61.6m (8-K Item 4.02)$83.9mn/a17.3
Margins are total company reported operating margins: HIMS and Lilly TTM Q3 2026, others for the period shown. Novo Nordisk in Danish kroner from its 6-K; Lilly, WW and LifeMD from Forms 10-Q; GoodRx from its 8-K Item 4.02. LifeMD and GoodRx latest available period is Q2 2026.

3 Sexual Health and Dermatology: The Subscriber Base Beyond Weight Loss

  • Subscribers 2.788m at 30 Sep 2026, +13% year on year and about 103,000 fewer than 2.891m at 30 Jun 2026, the first quarterly decline in the series shown; net additions were +307,000 in Q2 2026, the quarter Eucalyptus closed. Monthly revenue per average subscriber $105 against $81, about $10 lower excluding one time purchasers (8-K Ex 99.1).
  • Specialties (Q4 2025 letter): Weight Loss, Men's Dermatology, Sexual Health and Women's Dermatology each passed $100m of annual revenue in FY2025; Hims revenue grew more than 30% and Hers more than 100%; a majority of FY2025 revenue came from offerings other than GLP‑1. More than 1.6m subscribers were on a personalized solution and over 20% addressed more than one condition.
  • Brand mix (10-Q): Hers was about 45% of US revenue in Q3 2026 against about 40% in Q3 2025; a majority of US revenue in each 2026 quarter came from offerings other than GLP‑1.
  • Acquisition spending: customer acquisition cost $214.1m in Q3 2026 against $202.6m; marketing 28% of revenue against 39%. Wholesale revenue, mainly non prescription retail, was $36.2m in FY2025.

How telehealth and consumer health are changing

  • Teladoc (10-Q): revenue $605.1m in Q3 2026, (3.4%); BetterHelp segment $206.6m, (12.8%); operating margin (4.6%).
  • GoodRx and LifeMD: both delayed their Q3 2026 Forms 10-Q (NT 10-Q, 9 Nov 2026) for revenue recognition corrections; GoodRx expects to restate Q2 2026 revenue to $222.7m, +9.7%, from $200.4m as reported (preliminary, 8-K Item 4.02).
  • Drug makers selling direct: the FY2025 10-K names drug makers with direct to consumer channels among competitors; Novo Nordisk sells Wegovy through NovoCare and telehealth partners.
  • Scale: HIMS Q3 2026 revenue of $890.4m compares with $605.1m at Teladoc and $152.9m at WW International.
Figure 3.1 Subscribers and monthly revenue per average subscriber
Figure 3.2 Revenue growth of telehealth filers
Table 3.1 Telehealth and consumer health filers compared
CompanyLinePeriodDetailRevenueGrowth (%)Op. margin (%)
Hims & HersRevenueQ3 2026subscribers 2.788m; $105 per subscriber a month$890.4m48.6(7.4)
Teladoc HealthRevenueQ3 2026BetterHelp $206.6m (12.8% lower); Integrated Care $398.5m (+2.3%)$605.1m(3.4)(4.6)
GoodRxRevenue (preliminary restated)Q2 2026as reported $200.4m (1.3% lower)$222.7m9.717.3
LifeMDRevenue (as filed, under correction)Q2 2026gross margin 88.8%$47.3m(3.5)(15.1)
WW InternationalRevenueQ3 2026gross margin 71.1%$152.9m(11.2)23.9
Operating margins for the quarter shown; HIMS Q3 2026. GoodRx Q2 2026 as preliminary restated (8-K Item 4.02, 2 Nov 2026); LifeMD Q2 2026 as filed, subject to correction. Teladoc segments as filed.

4 International and New Specialties: Zava, Eucalyptus, Testosterone and Labs

  • Rest of the World revenue $233.3m in Q3 2026, +321% (10-Q), against $131.4m in Q2 2026 and $7.3m in Q1 2025. Eucalyptus was about 15% of Q3 2026 revenue and about 10% of 9M 2026 revenue (10-Q Note 3); Zava is not reported separately and was under 5% of FY2025 revenue.
  • Eucalyptus (closed 1 Jun 2026): purchase price $968.5m, of which $225.0m in cash at closing, $683.9m deferred over 18 months and an earn out at fair value of $59.6m; goodwill $790.3m. The 19 Feb 2026 release cited a Eucalyptus annual revenue run rate above $450m (non GAAP, Jan 2026) and more than 850,000 customers served, with the Juniper and Pilot brands in Australia, UK, Germany, Japan and Canada.
  • Other acquisitions: Zava Global (Jul 2025) for EUR 219.2m ($258.0m), with $45.7m of earn out paid in 9M 2026 based on FY2025 results; Medici Technologies in Canada (Nov 2025); YourBio Health, capillary blood sampling for lab testing (Jan 2026), for $153.0m.
  • New specialties (Q4 2025 letter): testosterone support, menopause and perimenopause care and lab testing launched in 2025; the letter expects each can exceed $100m of annual revenue. The Q3 2026 10-Q adds a risk factor on testosterone replacement therapy as a Schedule III controlled substance.

How international telehealth is changing

  • Novo Nordisk (6-K): International Operations sales DKK 37.32bn in Q3 2026, +8% at constant exchange rates; EUCAN DKK 19.86bn, +18%, with obesity sales +47%; the Wegovy pill launched in the UK and Germany by the end of Q3 2026.
  • Promotion rules: UK GPhC and MHRA rules prohibit promoting prescription only medicines to the public, and the UK, EU and Canada prohibit influencer promotion of prescription medicines (10-K FY2025 risk factors); the TGA in Australia is investigating Eucalyptus subsidiaries' 2023 to 2024 advertising, indemnified by the sellers (10-Q).
  • Revolver Amendment No. 5 (10-Q Ex 10.2): subsidiaries listed on Schedule 1.1(b) are excluded from guarantee requirements; each loses the exclusion once its own gross revenue over the last four quarters reaches 5% of consolidated gross revenue.
  • Teladoc non US revenue $115.9m in Q3 2026, (0.7%), 19% of its revenue.
Figure 4.1 Revenue by region by quarter
Figure 4.2 Purchase consideration of acquisitions
Table 4.1 International and new product revenue compared, Q3 2026
CompanyLinePeriodDetailRevenueGrowth (%)Op. margin (%)
Hims & HersRest of the World revenueQ3 202626.2% of revenue; Eucalyptus about 15% of revenue$233.3m+321 (filed)n/a
Novo NordiskInternational Operations salesQ3 2026constant exchange rates; EUCAN DKK 19.86bn (+18%)DKK 37.32bn8.0n/a
Teladoc HealthNon US revenueQ3 202619% of revenue$115.9m(0.7)n/a
Eli LillyFoundayo (orforglipron) revenueQ3 2026oral GLP‑1; $98m in Q2 2026$184.0mn/an/a
Hims & Hers Rest of the World growth as filed (10-Q). Novo Nordisk in Danish kroner at constant exchange rates (6-K); Teladoc and Lilly from their filings.

5 Financial Analysis & Ratios

  • GAAP operating income turned positive in FY2024 at $61.9m and reached $105.6m in FY2025 (4.5%); TTM Q3 2026 shows an operating loss of $232.5m ((8.1)%), which includes $41.9m of restructuring, $62.5m of legal contingencies and $77.6m of acquisition, transaction and earn out costs in 9M 2026. FY2024 net income of $126.0m included a $68.0m release of a valuation allowance.
  • Gross margin 82.0% in FY2023, 73.8% in FY2025 and 63.8% TTM; quarterly it fell from 73.5% in Q1 2025 to 57.2% in Q3 2026.
  • Free cash flow (company definition: operating cash flow less purchases of property, equipment, intangibles and internal use software) $57.4m in FY2025 after capex of $242.6m, and $8.2m TTM. 9M 2026 operating cash flow of $118.8m includes $433.3m of proceeds from receivables sold under the JPMorgan facility and a $351.2m rise in payables; receivables rose $323.9m, mainly manufacturer discount and rebate receivables on branded GLP‑1 inventory.
  • Balance sheet at 30 Sep 2026: cash and short term investments $712.2m; convertible notes $1.40bn principal ($1.37bn carrying); Eucalyptus deferred consideration $478.6m current and $84.5m non current; earn outs $170.7m; working capital (114.8m); equity $355.3m against $540.9m at 31 Dec 2025. Goodwill $1.11bn.
  • Buybacks: none in 9M 2026. The $250m program approved on 13 Nov 2025 runs to 11 Nov 2028; about $25m was used in Q4 2025, leaving $225m. Repurchases were $83.0m in FY2024 and $90.0m in FY2025. No dividend.
Table 5.1 Income statement, cash flow and balance sheet summary ($bn unless stated)
Line itemFY2021FY2022FY2023FY2024FY2025TTM Q3 2026
Revenue0.30.50.91.52.32.9
Gross profit0.20.40.71.21.71.8
Research and development0.00.00.00.10.1n/a
Selling, general and administrative0.20.40.60.81.2n/a
Operating income(0.1)(0.1)0.00.10.1(0.2)
Net income(0.1)(0.1)0.00.10.1(0.2)
Diluted EPS ($)(0.58)(0.32)(0.11)0.530.51n/a
Operating cash flow0.00.00.10.30.30.2
Capital expenditure0.00.00.0(0.1)(0.2)(0.2)
Free cash flow0.00.00.00.20.10.0
Stock based compensation0.10.00.10.10.10.2
Cash and investments0.20.20.20.30.90.7
Total debt0.00.00.00.01.01.4
Total equity0.30.30.30.50.50.4
Free cash flow follows the company definition. Total debt is the carrying value of the convertible notes; it excludes Eucalyptus deferred consideration and earn outs. Cash and investments include short and long term investments (FY2025 includes $351.3m of long term investments). TTM equals Q4 2025 plus Q1 to Q3 2026; TTM research and development (technology and development) and SG&A are not shown as quarterly cost lines were not collected.
Figure 5.1 Quarterly revenue and margins
Table 5.2 What changed, Q3 2026 against Q3 2025
MetricQ3 2025Q3 2026Change
Revenue ($bn)0.600.8948.6%
Gross profit ($bn)0.440.5115.2%
Operating income ($bn)0.01(0.07)n/a
Net income ($bn)0.02(0.03)n/a
Diluted EPS ($)0.06(0.14)n/a
Operating cash flow ($bn)0.150.07(56.0%)
Free cash flow ($bn)0.080.03(67.3%)
Operating margin (%)2.0(7.4)(9.4 pts)
Net margin (%)2.6(3.7)(6.3 pts)
Table 5.3 Ratio analysis
RatioFY2021FY2022FY2023FY2024FY2025TTM Q3 2026
Growth and margins
Revenue growth (%)n/a93.865.569.359.0n/a
Gross margin (%)75.277.682.079.573.863.8
Operating margin (%)(42.3)(13.0)(3.4)4.24.5(8.1)
Net margin (%)(39.6)(12.5)(2.7)8.55.5(6.6)
FCF margin (%)(14.5)(6.4)5.413.42.40.3
Cost and investment intensity
SBC (%) revenue24.78.17.66.35.86.2
Capex (%) revenue1.81.43.03.610.36.0
Returns
ROE (%)(32.2)(20.3)(7.2)30.725.2(53.7)
ROA (%)(25.6)(16.7)(5.8)21.99.0(5.4)
Asset turnover (x)0.651.441.982.091.090.81
Liquidity and leverage
Current ratio (x)3.414.523.001.791.900.92
Debt to equity (x)0.000.000.000.001.803.85
Net cash ($bn)0.20.20.20.30.0(0.7)
Efficiency and cash quality
Days sales outstandingn/an/an/an/a554
Inventory days746752774838
FCF to net income (x)n/an/an/a1.570.45n/a
ROE and ROA use average balances where both year ends are available, otherwise period end balances; TTM uses balances at 30 Sep 2026. Effective tax rates are omitted: FY2024 includes a $68.0m valuation allowance release and TTM pretax income is negative.
Figure 5.2 Margin profile
Figure 5.3 Operating cash flow, capital expenditure and free cash flow
Table 5.4 Valuation snapshot at $19.13 per share, 10 Nov 2026
MeasureValue
Market cap ($bn)4.5
Enterprise value ($bn)5.1
EV/Sales (TTM) (x)1.8
FCF yield (%)0.2
Price/Book (x)12.6
Table 5.5 Income statement, cash flow and balance sheet summary in $m
Line itemFY2021FY2022FY2023FY2024FY2025TTM Q3 2026
Revenue271.9526.9872.01,476.52,347.62,869.5
Gross profit204.5408.7714.91,173.11,733.41,831.2
Operating income (loss)(115.0)(68.7)(29.5)61.9105.6(232.5)
Net income (loss)(107.7)(65.7)(23.5)126.0128.4(190.8)
Adjusted EBITDA, non GAAPn/an/an/a176.9318.0253.3
Operating cash flow(34.4)(26.5)73.5251.1300.0180.1
Capital expenditure, company definition5.07.226.552.8242.6171.9
Free cash flow(39.4)(33.8)47.0198.357.48.2
Stock based compensation67.242.866.192.3135.2177.9
Share repurchases0.00.02.083.090.080.5
Cash and investments247.3179.6221.0300.3928.8712.2
Total debt, carrying value0.00.00.00.0972.61,367.4
Total equity334.6311.7344.0476.7540.9355.3
Same figures as Table 5.1 in $m, as most annual values are below $1bn. Adjusted EBITDA for FY2021 to FY2023 was not collected.

Cost structure and profitability

  • Cost of revenue and operating expenses (revenue less operating income) $956.5m in Q3 2026, +62.9%, against revenue +48.6%; GAAP operating margin (7.4)% against 2.0% a year earlier and (12.9)% in Q2 2026.
  • Gross margin 57.2% against 73.8% and 63.8% in Q2 2026; product and packaging costs +176% and shipping +64% (10-Q).
  • Marketing 28% of revenue in Q3 2026 against 39%; customer acquisition cost $214.1m against $202.6m; 9M 2026 $636.5m against $592.5m. In FY2025 marketing was 39.2% of revenue, operations and support 12.2%, technology and development 6.4% and G&A 11.6%.
  • From net loss to adjusted EBITDA in Q3 2026: stock based compensation $64.5m, depreciation and amortization $38.2m and acquisition, transaction and earn out costs $35.4m are added back; the $21.1m equity securities gain and $13.2m tax benefit are deducted. 9M 2026 adjusted EBITDA $187.0m against a GAAP net loss of $211.4m.
  • Operating cash flow $65.4m, capex $39.4m and free cash flow $26.0m in Q3 2026 against $148.7m, $69.4m and $79.4m; Q3 2026 receivables sales under the JPMorgan facility were $434.5m.
Figure 5.4 Costs as % of revenue by year
Figure 5.5 GAAP operating income and adjusted EBITDA by quarter
Figure 5.6 Q3 2026 net loss to adjusted EBITDA

Guidance, debt and capital return

  • FY2026 guidance in four steps (8-K Ex 99.1): 23 Feb 2026 revenue $2.7bn to $2.9bn and adjusted EBITDA $300m to $375m, excluding Eucalyptus; 11 May $2.8bn to $3.0bn and $275m to $350m; 10 Aug $3.1bn to $3.3bn and $275m to $325m, the first outlook after the Eucalyptus closing; 9 Nov $3.13bn to $3.15bn and $257m to $277m. The adjusted EBITDA midpoint fell from $337.5m to $267m.
  • Revenue against quarterly guidance: Q1 2026 $608.1m against $600m to $625m; Q2 2026 $753.2m against $680m to $700m; Q3 2026 $890.4m against $880m to $900m. The Q4 2026 range of $875m to $895m has a midpoint of $885m against Q3 2026 revenue of $890.4m.
  • Convertible notes: $1.00bn due 2030 convertible at $70.67 and $402.5m due 2032 convertible at $29.53, both 0% coupon; the close of $19.13 is below both conversion prices. Stated use of proceeds for the 2032 notes (8-K Ex 99.2, 19 May 2026): international expansion incl. Eucalyptus, technology and fulfillment infrastructure, AI capabilities and capped calls.
  • Buybacks: $225m remains under the $250m program to 11 Nov 2028; no shares were repurchased in 9M 2026, against $90.0m in FY2025.
Figure 5.7 FY2026 guidance history
Figure 5.8 Liquidity and obligations at 30 Sep 2026

6 MD&A & Management Commentary

Q3 2026 results, Form 10-Q and earnings release

  • Q3 2026 (10-Q and 8-K of 9 Nov 2026): revenue $890.4m, +49% and +18.2% on Q2 2026; net loss $33.0m against net income $15.8m; diluted EPS ($0.14) against $0.06; adjusted EBITDA $82.4m against $78.4m; free cash flow $26.0m against $79.4m.
  • 10-Q revenue analysis: US revenue $657.1m, +21%; Rest of the World $233.3m, +321%; Eucalyptus about 15% of revenue. The Hers brand was about 45% of US revenue; a majority of US revenue came from offerings other than GLP‑1. US weight loss memberships launched at the end of Mar 2026.
  • 10-Q costs: gross margin 57% against 74%; product and packaging costs +176% and shipping +64%. Marketing 28% of revenue against 39%; customer acquisition cost $214.1m against $202.6m. Restructuring for the US weight loss shift $41.9m in 9M 2026, of which $28.5m of inventory write downs in cost of revenue and $3.8m in Q3 2026.
  • Below operating income: gain on equity securities $21.1m and income tax benefit $13.2m in Q3 2026 reduced the net loss to $33.0m from an operating loss of $66.1m. 9M 2026 interest expense $12.1m.
Table 6.1 FY2026 guidance history and the 2026 quarterly track record (8-K Ex 99.1)
ItemOutlookSource
FY2026, set 23 Feb 2026revenue $2.7bn to $2.9bn; adjusted EBITDA $300m to $375m (11% to 13% margin); excludes Eucalyptus; assumes continued access to compounded semaglutide8-K Ex 99.1
FY2026, set 11 May 2026revenue $2.8bn to $3.0bn; adjusted EBITDA $275m to $350m (10% to 12% margin); excludes Eucalyptus; after March 2026 shift to branded GLP‑18-K Ex 99.1
FY2026, set 10 Aug 2026revenue $3.1bn to $3.3bn; adjusted EBITDA $275m to $325m (9% to 10% margin); first outlook after the Eucalyptus closing on 1 Jun 20268-K Ex 99.1
FY2026, set 9 Nov 2026revenue $3.13bn to $3.15bn; adjusted EBITDA $257m to $277m (8% to 9% margin); midpoint revenue $3.14bn; midpoint EBITDA cut by $33m vs August8-K Ex 99.1
Q1 2026revenue $600m to $625m, actual $608.1m; adjusted EBITDA $35m to $55m, actual $44.3m8-K Ex 99.1
Q2 2026revenue $680m to $700m, actual $753.2m; adjusted EBITDA $35m to $55m, actual $60.3m8-K Ex 99.1
Q3 2026revenue $880m to $900m, actual $890.4m; adjusted EBITDA $75m to $95m, actual $82.4m8-K Ex 99.1
Q4 2026revenue $875m to $895m, +42% to +45% on Q4 2025 ($617.8m); adjusted EBITDA $70m to $90m (8% to 10% margin)8-K Ex 99.1, 9 Nov 2026
2030 targetsat least $6.5bn revenue and $1.3bn adjusted EBITDAQ4 2025 letter; reiterated in 2026 releases

Management and CFO commentary

  • CFO Yemi Okupe, Q3 2026 release (8-K Ex 99.1): revenue grew 49%, the second consecutive quarter of faster growth; domestic revenue +21% and international more than +300%; marketing spend was paced ahead of several planned platform expansions in Q4 2026.
  • CEO Andrew Dudum, Q3 2026 release: Hims & Hers is expanding the treatments and specialties available and rolling out an AI native experience to support each customer's care.
  • Q2 2026 release (10 Aug 2026): the CFO expected domestic growth to keep accelerating through H2 2026 and raised the FY2026 revenue outlook; international grew more than 17 fold with Eucalyptus closing in June; the CEO cited nearly 3 million people on the platform.
  • Q1 2026 release (11 May 2026): the pivot to branded GLP‑1 products widened the assortment; nearly 2.6m subscribers; Hims & Hers moved from a quarterly to an annual shareholder letter.
  • Q4 2025 letter (23 Feb 2026): FY2025 gross margin about 74%, lower on international mix, new offerings and shorter shipping cadences; liquidity $929m at year end and about $1bn of convertible debt; Q4 2025 free cash flow ($3m) on capex for pharmacy automation.
Table 6.2 Management statements in their own words
SpeakerDate and sourceStatement
Andrew Dudum, CEO9 Nov 2026, 8-K Ex 99.1 Q3 2026“In healthcare, whoever owns the customer relationship wins”
Yemi Okupe, CFO9 Nov 2026, 8-K Ex 99.1 Q3 2026“Revenue grew 49% year‑over‑year, our second consecutive quarter of acceleration”
Andrew Dudum, CEO11 May 2026, 8-K Ex 99.1 Q1 2026“2026 is a defining year for Hims & Hers.”
Table 6.3 Key disclosures in the Forms 10-Q and 10-K
ItemDisclosure
10-Q Q3 2026, gross margin57% against 74%; product and packaging costs +176%, shipping +64%; management expects gross margin below prior periods in the near term.
10-Q Q3 2026, weight lossMarch 2026 shift to branded GLP‑1 (Novo Nordisk products) with compounded GLP‑1 on a limited scale; shorter shipping cadences lower gross margin and shift revenue timing.
10-Q Q3 2026, liquidityWorking capital deficit $114.8m driven by $478.6m of current Eucalyptus deferred consideration, which can be settled mostly in shares (cap 19.9%); revolver $161.0m available; receivables facility $400m uncommitted; contractual obligations $1.08bn, $607.0m within 12 months.
10-Q Q3 2026, adjusted EBITDADefinition revised in Q2 2025 (payroll tax on stock compensation), Q1 2026 (restructuring) and Q3 2026 (FX gains and losses, not recast).
10-Q Q3 2026, legalFTC, Utah and Los Angeles County lawsuit of 29 Jul 2026 (FTC Act Section 5, ROSCA), about $60m accrued, motion to dismiss hearing 14 Jan 2027; SEC Division of Enforcement investigation since Feb 2026 on compounded semaglutide disclosures; HHS referral to the DOJ in Feb 2026; Velanki securities class action filed 1 Sep 2026.
10-Q Q3 2026, exhibitsEx 10.2: revolving credit facility Amendment No. 5 (25 Aug 2026) on guarantor exclusions; Ex 10.3: Amending Deed No. 2 to the Eucalyptus Securities Sale Deed (29 Sep 2026) on deferred payment timing.
10-K FY2025, competitionHims & Hers believes no direct competitor offers its full suite; it competes with traditional providers, pharmacies, retailers, niche telehealth firms, compounders and drug makers selling direct to consumers.
10-K FY2025, controlsControls effective at 31 Dec 2025; Zava excluded from the assessment (under 3% of assets, under 5% of revenue).
10-K FY2025, investmentOver $300m of capital spending over three years and over 1 million square feet of US facilities (Q4 2025 letter); FY2025 capex $242.6m.

7 Peer Valuation & Sector Summary

  • Sector: direct to consumer telehealth and cash pay prescriptions in weight loss, sexual health, dermatology and hormone health. The FY2025 10-K competition section names no companies; the peer table uses US listed filers in the categories it describes (telehealth providers, niche direct to consumer health firms and drug makers selling direct) and in the weight loss market: Teladoc, LifeMD, GoodRx, WW International, Eli Lilly and Novo Nordisk.
  • Growth, latest quarter: HIMS +48.6% (Q3 2026); LLY +38.6% (Q3 2026); GDRX +9.7% (Q2 2026, preliminary restated); NVO +4.0% (Q3 2026, constant exchange rates); TDOC (3.4%) (Q3 2026); LFMD (3.5%) (Q2 2026, as filed); WW (11.2%) (Q3 2026).
  • Restatements: GoodRx and LifeMD both filed NT 10-Q for Q3 2026 on 9 Nov 2026, so their latest figures are Q2 2026. GoodRx expects to restate Q2 2026 revenue to $222.7m from $200.4m (preliminary, 8-K Item 4.02, 2 Nov 2026); LifeMD is correcting revenue over recognized from 2024 to Q2 2026.
  • Margins: HIMS GAAP operating margin (8.1)% TTM against LLY 40.3%, NVO 29.1%, WW 23.9%, GDRX 17.3%, TDOC (4.6%) and LFMD (15.1%). HIMS EV/Sales 1.8x TTM against LLY 16.1x.
Table 7.1 Peer comparison, latest reported trailing twelve months
CompanyRevenue TTM ($bn)Revenue growth (%)Gross margin (%)Operating margin (%)Net margin (%)FCF margin (%)ROE (%)Net cash ($bn)Market value ($bn)EV/Sales (x)P/E TTM (x)
HIMS2.948.663.8(8.1)(6.7)0.3(53.7)(0.7)41.8n/a
TDOCn/a(3.4)n/a(4.6)(4.5)n/an/an/a2n/an/a
GDRXn/a9.7n/a17.38.8n/an/a(0.2)1n/an/a
LFMDn/a(3.5)88.8(15.1)(15.0)n/an/an/a0n/an/a
WWn/a(11.2)71.123.99.9n/an/a(0.3)0n/an/a
LLY86.538.683.640.331.922.782.6(44.6)1,34716.146.5
NVOn/a4.077.029.121.136.0n/an/an/an/an/a
Growth is for the latest quarter year on year. Periods differ: HIMS and LLY TTM Q3 2026 for margins, ROE and EV/Sales and Q3 2026 for growth; TDOC, WW and NVO Q3 2026; GDRX and LFMD Q2 2026, as both filed NT 10-Q for Q3 2026 (GoodRx restating Q1 and Q2 2026 upward under Item 4.02; LifeMD correcting revenue over recognized from 2024 to Q2 2026). NVO growth at constant exchange rates; NVO market value not computed. HIMS net cash is cash and investments less convertible principal and excludes $563.1m of Eucalyptus deferred payables. Market values use closes of 10 Nov 2026.
Figure 7.1 Revenue growth versus operating margin, peer set

8 Material Events & Contracts

  • Fifteen Forms 8-K from 11 Nov 2025 to 11 Nov 2026: four earnings releases, the Eucalyptus agreement and closing, the March 2026 weight loss shift, the 2032 convertible notes, the receivables facility, the annual meeting, the buyback program, the principal accounting officer handover and the board appointment of 9 Nov 2026.
  • Board appointment (8-K of 9 Nov 2026, Item 5.02): Dr. Andrew Huberman became a non independent director on 4 Nov 2026 with no committee seat. The 8-K also discloses related paid agreements: an advisory agreement at $3.5m a year for two years plus up to $1.0m a year for short form videos, and a podcast marketing agreement of up to three years with Scicomm Media, which he co founded and co owns, at $5.0m a year, of which his interest is about $2.1m a year. Fees under both agreements total up to $9.5m a year while both run.
  • Principal accounting officer handover: Irene Becklund resigned as Chief Accounting Officer effective 9 Oct 2026 (8-K of 17 Jul 2026) and Jonathan Franklin, who joined as chief accounting officer on 5 Oct 2026, became principal accounting officer on the same date (8-K of 7 Oct 2026).
  • Legal and regulatory matters (10-Q): SEC Division of Enforcement investigation opened in Feb 2026 on compounded semaglutide disclosures; HHS referred Hims & Hers to the DOJ in Feb 2026 after an FDA statement naming the company; FTC, Utah and Los Angeles County lawsuit of 29 Jul 2026 under FTC Act Section 5 and ROSCA, with about $60m accrued and legal contingencies of $62.5m in 9M 2026; Velanki securities class action of 1 Sep 2026; TGA investigation of Eucalyptus subsidiaries, indemnified by the sellers. A Novo Nordisk patent suit of 9 Feb 2026 was dismissed without prejudice on 9 Mar 2026.
Table 8.1 Forms 8-K filed in the last twelve months
DateItemsEvent
9 Nov 20265.02Board appointment (event 4 Nov 2026): board expanded from nine to ten; Dr. Andrew Huberman appointed a non independent director with no committee seat; $50,000 cash retainer and $250,000 annual equity award, prorated. Related paid agreements of 5 Nov 2026: two year advisory agreement at $3.5m a year in cash plus up to $1.0m a year for short form videos; podcast marketing agreement of up to three years with Scicomm Media, which he co founded and co owns, at $5.0m a year, his interest about $2.1m a year. No exhibit; agreements to be filed with the FY2026 10-K.
9 Nov 20262.02, 8.01, 9.01Q3 2026 results (Ex 99.1): revenue $890.4m, +49%; gross margin 57%; net loss $33.0m; adjusted EBITDA $82.4m; subscribers 2.788m. Q4 2026 guidance revenue $875m to $895m, adjusted EBITDA $70m to $90m; FY2026 revenue $3.13bn to $3.15bn, adjusted EBITDA $257m to $277m.
7 Oct 20265.02Jonathan Franklin, former VP Corporate Controller of Rivian, joined as chief accounting officer on 5 Oct 2026 and was appointed principal accounting officer effective 9 Oct 2026: salary $425,000, $150,000 signing bonus, $3.0m RSU grant, 50% target bonus.
10 Aug 20262.02, 9.01Q2 2026 results: revenue $753.2m, +38%; net loss $86.3m; adjusted EBITDA $60.3m; subscribers 2.891m. FY2026 revenue guidance raised to $3.1bn to $3.3bn; adjusted EBITDA lowered to $275m to $325m.
17 Jul 20265.02Chief Accounting Officer Irene Becklund to resign effective 9 Oct 2026; advisory agreement to 10 Jul 2027. No exhibit.
1 Jul 20261.01, 2.03, 9.01Master Receivables Purchase Agreement with JPMorgan Chase (Ex 10.1): $400m limit, 364 day term, parent performance undertaking. Revolving credit facility Amendment No. 4 of 26 Jun 2026 (Ex 10.2) adds a $400m debt basket for it.
15 Jun 20265.07Annual meeting of 11 Jun 2026: nine directors elected, KPMG ratified, advisory say on pay approved. No exhibit.
2 Jun 20261.01, 2.03, 8.01, 9.01Revolving credit facility Amendment No. 3 of 29 May 2026 (Ex 10.1) to permit the Eucalyptus closing; release on completion of the Eucalyptus acquisition on 1 Jun 2026 (Ex 99.1), 850,000 customers served.
21 May 20261.01, 2.03, 3.02, 9.01Issued $402.5m of 0% convertible senior notes due 1 Jun 2032 (indenture Ex 4.1); capped calls costing about $36.7m with HSBC, Barclays, BNP Paribas, Truist and Morgan Stanley (Ex 10.1, 10.2).
19 May 20268.01, 9.01Announced and priced an upsized $350m convertible notes offering due 2032 plus a $52.5m option; conversion price about $29.53, 32.5% above the $22.29 close of 18 May 2026; cap price $50.15 (Ex 99.1, 99.2).
11 May 20262.02, 9.01Q1 2026 results: revenue $608.1m, +4%; net loss $92.1m; adjusted EBITDA $44.3m; subscribers 2.584m. FY2026 guidance revenue $2.8bn to $3.0bn, adjusted EBITDA $275m to $350m. Move to an annual shareholder letter.
11 Mar 20267.01, 9.01Release of 9 Mar 2026: US weight loss shifts to FDA approved GLP‑1s under an agreement with Novo Nordisk to offer Ozempic and Wegovy pills and injections; compounded GLP‑1 no longer advertised and offered on a limited scale; Novo Nordisk dismissed its patent suit without prejudice.
23 Feb 20262.02, 9.01Q4 and FY2025 results (Ex 99.1 release, Ex 99.2 letter): FY2025 revenue $2.35bn, +59%; net income $128.4m; adjusted EBITDA $318.0m. FY2026 guidance revenue $2.7bn to $2.9bn, adjusted EBITDA $300m to $375m; 2030 targets of at least $6.5bn revenue and $1.3bn adjusted EBITDA.
19 Feb 20261.01, 3.02, 7.01, 9.01Securities Sale Deed to acquire Eucalyptus (Ex 2.1) for up to about $1.15bn: about $240m upfront, about $710m deferred over 18 months, up to about $200m of earn outs; up to about 60% of deferred and earn out payments may be paid in Class A shares (Ex 99.1).
17 Nov 20258.01Share repurchase program of up to $250m through 11 Nov 2028 (approved 13 Nov 2025); 1,334,572 shares bought for $55.5m from 1 Oct to 7 Nov 2025 completed the $100m 2024 program.
Table 8.2 Material contracts and financing arrangements
ContractTerms
0% convertible senior notes due 2030$1.00bn issued May 2025, maturity 15 May 2030, conversion price $70.67; capped calls $47.8m; redeemable from 19 May 2028; carrying $977.2m, fair value $858.8m at 30 Sep 2026.
0% convertible senior notes due 2032$402.5m issued 21 May 2026, maturity 1 Jun 2032, conversion price $29.53 (32.5% premium); capped calls $36.7m with cap $50.15; net proceeds $389.5m; redeemable from 6 Jun 2029; fair value $503.8m at 30 Sep 2026.
Revolving credit and guaranty agreement (JPMorgan, agent)$175m to 18 Feb 2028, accordion $125m; term SOFR plus 0.10% plus 1.50% to 2.00%; total leverage at most 3.50x, interest coverage at least 3.00x; undrawn, $14.0m letters of credit, $161.0m available at 30 Sep 2026.
Revolver amendmentsNo. 1 (25 Jun 2025); No. 2 (7 May 2026): investments added to cash equivalents in the leverage ratio; No. 3 (29 May 2026): Eucalyptus closing, joinder of material foreign subsidiaries; No. 4 (26 Jun 2026): $400m basket for the receivables facility; No. 5 (25 Aug 2026, 10-Q Ex 10.2): subsidiaries on Schedule 1.1(b) excluded from guarantees, each until its own four quarter gross revenue reaches 5% of consolidated gross revenue.
Master Receivables Purchase AgreementJPMorgan Chase as purchaser, signed 1 Jul 2026, $400m limit, 364 days, extendable, uncommitted; sellers XeCare and Apostrophe Pharmacy; true sale. Q3 2026: $434.5m of receivables sold for $433.3m, in operating cash flow.
Eucalyptus Securities Sale Deed and amendmentsPurchase price $968.5m: $225.0m upfront, $683.9m deferred in six instalments over 18 months from 1 Jun 2026, earn out fair value $59.6m (maximum $96.6m); $130.3m paid in 9M 2026; most deferred and earn out amounts may be paid in Class A shares, capped at 19.9%. Amending Deed No. 2 of 29 Sep 2026 (10-Q Ex 10.3) changes payment timing in clause 4.2(b).
Novo Nordisk collaborationAgreement announced 9 Mar 2026 to offer Ozempic and Wegovy pills and injections on the platform; financial terms not filed.
Huberman agreements (5 Nov 2026)Advisory agreement $3.5m a year for two years plus up to $1.0m a year for videos; podcast marketing agreement with Scicomm Media $5.0m a year for up to three years; to be filed with the FY2026 10-K.

9 Ownership, Voting Power & Annual Meeting

  • Dual class control: Class V shares carry 175 votes each. CEO Andrew Dudum controls 87.7% of total voting power through trusts holding all 8,377,623 Class V shares, plus Class A shares and options (2026 proxy). Directors and executive officers as a group held 8.44% of Class A and 87.93% of voting power.
  • Institutions (2026 proxy): BlackRock 10.35% of Class A (1.36% of votes); Capital World Investors 6.43%.
  • 2026 annual meeting (11 Jun 2026): all nine directors elected; Kofi Amoo‑Gottfried was a new nominee. The lowest support was 98.9% of votes cast for David Wells. Say on pay 99.3%; KPMG ratified with 100.0%. Votes count as one class, so Class V decides every item.
  • Insiders, 12 months to 11 Nov 2026 (113 Forms 4): 45 open market or plan sales by officers and directors for about $19.3m, many under Rule 10b5‑1 plans: CFO Yemi Okupe $9.7m, COO Mike Chi $3.8m, CLO Soleil Boughton $1.8m, CMO $1.2m, CTO $1.2m, former principal accounting officer Irene Becklund $0.8m, CPO $0.7m and director Andrea Perez $0.1m. About $59.1m of shares were withheld for taxes on vesting.
  • Purchases and transfers: director David Wells bought 48,400 shares for $1.17m at about $24.24 on 26 May 2026, the only open market purchase. CEO Dudum made no open market sales; a trust distributed 977,566 shares on 27 Aug 2026 and he gifted 463,289 shares on 25 Aug 2026. Performance share units earned on 23 Feb 2026: Dudum 794,002, Okupe 410,690, Chi 365,058 and Boughton 273,794 shares.
Table 9.1 Annual meeting vote results, 11 Jun 2026
ProposalFor (bn votes)Against (bn votes)Abstain (bn votes)For as % of votes castResult
Election of Andrew Dudum1.5050.013none (plurality vote)99.1elected
Election of Kofi Amoo‑Gottfried1.5170.001none (plurality vote)100.0elected
Election of Deborah Autor1.5160.002none (plurality vote)99.9elected
Election of Delos Cosgrove1.5170.001none (plurality vote)99.9elected
Election of Anja Manuel1.5170.001none (plurality vote)99.9elected
Election of Christopher Payne1.5090.009none (plurality vote)99.4elected
Election of Andrea Perez1.5170.001none (plurality vote)99.9elected
Election of Kare Schultz1.5170.001none (plurality vote)99.9elected
Election of David Wells1.5020.016none (plurality vote)98.9elected
Ratify KPMG for FY20261.5910.0010.000100.0approved
Advisory say on pay1.5060.0110.00099.3approved
Directors are elected by plurality; the against column shows votes withheld. Broker non votes 74.2m on every item except the auditor ratification. Class A carries one vote and Class V 175 votes per share, voting as one class.

Annual meeting remarks

  • The Form 8-K Item 5.07 reports vote counts only; no management remarks, presentation or shareholder questions from the virtual meeting of 11 Jun 2026 were filed.
Table 9.2 Largest holders and voting power
HolderClass A (m)Class V (m)Share of class or votesSource
Andrew Dudum (CEO), incl. trusts15.398.3887.73% of votes2026 proxy
BlackRock23.0510.35% of Class A; 1.36% of votes2026 proxy
Capital World Investors14.326.43% of Class A2026 proxy
Directors and executive officers as a group18.798.388.44% of Class A; 87.93% of votes2026 proxy
Proxy figures as filed on 28 Apr 2026. Class V carries 175 votes per share and is held by trusts affiliated with the CEO. Shares outstanding at 6 Nov 2026: 226.03m Class A and 8.38m Class V (10-Q cover).

10 Risk Factors

  • Item 1A grew from 63 risk factors in the FY2024 10-K to 71 in the FY2025 10-K and 73 in the Q3 2026 10-Q (28,690, 33,360 and 35,140 words): the FY2025 10-K added 8 factors, removed 0 and materially reworded 12. The 2026 Forms 10-Q restate the section in full; the Q2 2026 10-Q added AI spending and convertible debt risks and the Q3 2026 10-Q added testosterone therapy as a controlled substance risk.
Table 10.1 Risk factors with filed figures
RiskDisclosure and change
Compounding and the branded GLP‑1 shift (reworded in FY2025 10-K and Q1 2026 10-Q)End of the semaglutide shortage on 21 Feb 2025 limited 503B compounding; the Feb 2026 FDA statement named Hims & Hers. Restructuring $41.9m in 9M 2026; gross margin 57.2% in Q3 2026.
Government actions and public statements (added, FY2025 10-K)FDA warning letters (Sep and Dec 2025), Feb 2026 FDA statement and HHS referral to the DOJ, SEC investigation since Feb 2026 and the FTC lawsuit of 29 Jul 2026 with about $60m accrued.
Eucalyptus acquisition and funding (added, FY2025 10-K)Deferred and earn out payments could strain cash or dilute holders if settled in shares; deferred payable $563.1m at 30 Sep 2026, earn outs $170.7m in total.
Indebtedness and convertible notes (added, Q2 2026 10-Q)$1.40bn of convertible principal; conversion prices $70.67 and $29.53 against a $19.13 close.
AI investments (added, Q2 2026 10-Q)Investment in AI may not deliver the expected benefits; the Q3 2026 release describes an AI native experience being rolled out.
Testosterone replacement therapy (added, Q3 2026 10-Q)The 2026 launch includes Schedule III controlled substances, which require DEA registration and state compliance.
Influencers and promotion outside the US (reworded)UK, EU and Canadian rules prohibit promotion of prescription only medicines to the public, incl. influencer promotion of weight loss treatments; Rest of the World was 26.2% of Q3 2026 revenue.
Dual class structureCEO Andrew Dudum controls 87.7% of voting power through Class V shares with 175 votes each.

How risk factors changed

  • Comparison: 10-K FY2025 filed 23 Feb 2026 acc 0001773751-26-000022 against 10-K FY2024 filed 24 Feb 2025 acc 0001773751-25-000062.
  • Risk factors rose from 63 (FY2024 10-K) to 71 (FY2025 10-K) and 73 (Q3 2026 10-Q); words from 28,690 to 33,360 and 35,140.
  • GLP‑1 is named in 9 factors in the FY2025 10-K against 6 a year earlier; compounding appears in 20 against 16.
  • UK, EU or Canada are named in 8 factors in FY2025 against 1 in FY2024, and Australia appears in 5 factors by Q3 2026 after Eucalyptus.
  • Government action moved from general to specific: FDA warning letters (Sep and Dec 2025), Feb 2026 FDA statement, HHS DOJ referral, SEC investigation and the Jul 2026 FTC lawsuit.
  • Q2 2026 added capital structure risks (AI spending, $1.4bn convertibles); Q3 2026 added controlled substance risk from testosterone therapy.
Figure 10.1 Risk factors by change against the prior filing
Table 10.2 Size of the risk factor section
Measure10-K FY202410-K FY2025
Risk factors (count)6371
Words in Item 1A28,69033,360
Table 10.3 Risk factors added, removed and materially reworded
ChangeRisk factorWhat changed
AddedEucalyptus deal subject to conditions, may not closeNew section on the 19 Feb 2026 deal: closing depends on regulatory approvals and other conditions under New South Wales law.
AddedFunding plan for Eucalyptus exposed to weaker resultsUpfront, deferred (18 months) and earn out payments could strain cash if operating results or capital markets weaken; share settlement could dilute holders.
AddedExpected benefits of Eucalyptus may not be realizedIntegration of operations in Australia, UK, Germany, Canada and Japan may not deliver anticipated growth.
AddedFDA warning letters on specimen collection kitsFDA has issued warning letters on at home specimen collection kits; similar action against kits used for the Labs offering could disrupt it.
AddedFDA regulation of laboratory developed testsNew exposure from the lab testing facility and Labs offering launched in 2025 to LDT rules in the US and diagnostic rules abroad.
AddedSample collection kits as prescription devices need state licensesKits could be deemed prescription devices requiring state distribution licenses, 510(k) or other FDA authorization.
AddedPerceptions of compounded drug safety and qualityNegative public perception of compounded drugs, including GLP‑1s, could reduce demand and harm the business.
AddedActions and public statements by US officials and agenciesCites Sep 2025 FDA warning letters on compounded semaglutide website claims and the Feb 2026 HHS statement referring the company to the DOJ.
RewordedExpanding or maintaining scope of offeringsReplaces the 2024 shortage narrative with the 21 Feb 2025 end of the semaglutide shortage, limits on 503B compounding and the Feb 2026 FDA statement naming the company.
RewordedPharmacy business adds healthcare regulationAdds UK GPhC and MHRA rules and Canadian provincial pharmacy regulation after Zava and Medici; drops text on not owning XeCare and Apostrophe Pharmacy (now wholly owned).
RewordedFailure to comply with healthcare lawsGrows from 1,779 to 2,229 words: Dec 2025 warning letter to the 503B Outsourcing Facility, Feb 2026 FDA statement and HHS DOJ referral, peptide facility (Feb 2025), Zava and Medici foreign regimes.
RewordedFines for promoting unapproved uses or drugsExtends to UK, EU and Canada regulators and their ban on promoting prescription only medicines; notes prior FDA warning letters on promotion of compounded products.
RewordedPublic scrutiny of privacy and securityGrows from 626 to 992 words with EU GDPR, UK GDPR transfer rules and Canadian privacy and AI rules.
RewordedUse of social media and influencersHeading drops 'celebrity'; adds UK, EU and Canada prohibition on influencer promotion of prescription medicines, especially weight loss treatments.
RewordedInternational expansion important for growthHeading drops 'long‑term'; lists Zava (Jul 2025), Medici (Nov 2025) and the Feb 2026 Eucalyptus agreement.
RewordedAnti‑kickback, self referral and false claims lawsAdds whistleblower provisions of the False Claims Act and clarifies that the company does not accept third party payor payments in the US.
RewordedClaims of infringing others' intellectual propertyHeading now says the company 'is' subject to such claims; cites the 9 Feb 2026 Novo Nordisk patent suit over compounded semaglutide.
RewordedLegal and regulatory proceedings and inquiriesHeading adds 'regulatory' proceedings and inquiries; text adds securities class action and derivative suits and the FTC information requests.
RewordedEstimates in main accounting policiesAdds valuation of acquired assets, intangible useful lives, deferred tax assets, inventory and refund reserve estimates.
RewordedClass A stock price volatileHeading changed from 'may be volatile' to 'has been and may continue to be volatile'.
Table 10.4 Risk factor updates in quarterly reports since the annual filing
FilingChange disclosed
10-Q Q1 2026 filed 11 May 2026Full Item 1A restated; 71 factors, 4 materially reworded: March 2026 shift to branded GLP‑1 with limited compounding, legal proceedings text adds FTC findings (Apr 2026), settlement talks and Feb 2026 SEC Enforcement investigation, cybersecurity factor adds the Feb 2026 social engineering incident, profitability factor cites Q1 2026 net loss of $92.1m.
10-Q Q2 2026 filed 10 Aug 2026Groups regrouped into four; 72 factors. Added: AI investments may not deliver benefits; indebtedness and liabilities ($1.4bn convertible principal at 30 Jun 2026); ability to fund convertible repurchase or conversion. Removed: two Eucalyptus closing and benefit factors after the 1 Jun 2026 close. Privacy factor rewritten (768 to 1,432 words); legal factor names the FTC investigation under the FTC Act and ROSCA.
10-Q Q3 2026 filed 9 Nov 202673 factors. Added: testosterone replacement therapy launched in 2026 includes Schedule III controlled substances (DEA registration, state rules). Reworded: supply chain factor drops branded GLP‑1 supply constraint text; security factor adds AI enabled attacks; Russia and Ukraine references removed from macro factors.

11 Stock Price, Scenarios & Sensitivity

  • HIMS closed at $19.13 on 10 Nov 2026, 16.6% below the $22.94 close of 6 Nov 2026; the Q3 2026 results were released on 9 Nov 2026. The price is 53.3% below the 52 week high of $40.99 (5 Dec 2025) and 39.2% above the low of $13.74 (23 Feb 2026); the five year high in monthly closes was $66.18 in Jul 2025.
  • Valuation on an EV/Sales basis: market value $4.48bn on 234.41m Class A and Class V shares, Class V valued at the Class A price; enterprise value $5.14bn after convertible notes at carrying value less cash; EV/Sales 1.8x TTM. P/E and GAAP EV/EBITDA are not meaningful as TTM net income and GAAP EBITDA are negative; EV to TTM adjusted EBITDA (non GAAP, $253.3m) is 20.3x.
  • Scenario model uses exit EV/Sales: revenue grows from TTM Q3 2026 $2.87bn for three years; implied price equals TTM Q3 2029 revenue times exit EV/Sales less net debt of $0.69bn (convertible principal less cash), divided by 260m shares, which allows for dilution from the convertible notes and share settled Eucalyptus payments. The exit multiples of 3.0x (best), 1.2x (base) and 0.8x (worst), the revenue growth rates and the 260m share count are model assumptions set for this report. The best and base multiples approximate the EV/Sales implied by a GAAP operating margin of 12% and 6% at a P/E of 30x and 22x.
Figure 11.1 HIMS monthly closing price and three year scenarios

Critical factors and core assumptions

Table 11.1 Critical factors behind the best case
FactorCurrent valueBest case requiresEvidence in filings and calls
US revenue after the branded GLP‑1 shift$657.1m in Q3 2026, +21%US growth of 15% to 20% a yearUS growth (8%) in Q1, +16% in Q2, +21% in Q3 2026 (8-K Ex 99.1)
Gross margin57.2% in Q3 2026recovery to about 60% to 65%73.8% in Q3 2025; 10-Q expects gross margin below prior periods near term
International scaleRest of the World $233.3m, 26.2% of revenueabove $1bn a year with positive adjusted EBITDAQ3 2025 letter: international markets above $1bn of revenue potential
Subscriber growth2.788m, +13%, about 103,000 fewer than Q2 2026growth back above 15% a year2.891m at Q2 2026 (8-K Ex 99.1)
Legal and regulatory outcomeabout $60m FTC accrual; SEC investigation; DOJ referral; securities suitsresolution near the accrued amount without business restrictions10-Q legal proceedings note
Dilution and capital234.41m shares; $1.40bn convertibles; $563.1m Eucalyptus deferreddeferred payments made in cash from operating cash flowshare settlement option capped at 19.9% (10-Q)
  • Revenue base TTM Q3 2026 $2.87bn; FY2026 guidance $3.13bn to $3.15bn; 2030 company targets of at least $6.5bn revenue and $1.3bn adjusted EBITDA.
  • Best case: 22% revenue CAGR, close to the path to the 2030 target; international above $1bn; branded GLP‑1 memberships and new specialties (testosterone, menopause, labs) each above $100m; gross margin near 60%; exit EV/Sales 3.0x.
  • Base case: 14% revenue CAGR from the FY2026 guidance midpoint of $3.14bn; adjusted EBITDA margin back toward 12% to 13%; exit EV/Sales 1.2x.
  • Worst case: 4% revenue CAGR with lower US growth from branded GLP‑1 economics and the FTC, SEC and DOJ matters, subscribers stay near 2.8m and Eucalyptus payments are settled in shares; exit EV/Sales 0.8x.
  • Shares 260m against 234.41m today, allowing for convertible and Eucalyptus dilution; net debt held at $0.69bn; no dividends; buybacks discretionary under the $225m authorization.

Scenarios, three years forward

Table 11.2 Scenario analysis, TTM Q3 2026 to TTM Q3 2029
MeasureWorst caseBase caseBest case
Revenue CAGR, 3 years (%)4.014.022.0
Revenue, TTM Q3 2029 ($bn)3.24.35.2
Exit EV/Sales (x)0.81.23.0
Implied price ($)71757
Change against $19.13 (%)(62)(11)200
Implied annual return (%)(27.5)(3.9)44.3
DescriptionLow US growth; legal costs; share settled paymentsMid teens growth from the FY2026 guidance midpointInternational above $1bn; new specialties scale; gross margin near 60%
Implied price = (TTM Q3 2029 revenue x exit EV/Sales less net debt $0.69bn) / 260m shares. Growth rates, exit multiples and share count are model assumptions; margins do not enter the EV/Sales calculation. Change and return are measured against the close of $19.13 on 10 Nov 2026. Eucalyptus deferred payables are not deducted, as most can be settled in shares.
Figure 11.2 Three year price scenarios

Sensitivity analysis

Table 11.3 Sensitivity of implied price to revenue CAGR and exit EV/Sales
Revenue CAGR \ EV/Sales1x2x3x4x
0%$8$19$30$41
4%$10$22$35$47
9%$12$26$40$55
14%$14$30$46$63
18%$15$34$52$70
22%$17$37$57$78
Cells show implied share price in year 3. Close on 10 Nov 2026 $19.13. Blue cells sit above it, red cells below. EV/Sales basis on TTM Q3 2029 revenue; net debt held flat; 260m shares.

Disclaimer

This analysis is for information only and is not financial advice. It is derived from public SEC filings retrieved via sec-api.io and is not a publication of the U.S. Securities and Exchange Commission. Scenario values are model outputs under stated assumptions and are not forecasts. Data as of 10 November 2026.

Sources

All company and peer figures are read from SEC filings retrieved through the sec-api.io MCP server. Share prices are closing prices.

Table A.1 Filings used, with accession numbers
FormPeriodFiledAccession number
10-QQ3 20269 Nov 20260001773751-26-000246
8-K Ex 99.1Q3 20269 Nov 20260001773751-26-000242
8-K Item 5.024 Nov 20269 Nov 20260001773751-26-000245
10-QQ2 202610 Aug 20260001773751-26-000163
10-QQ1 202611 May 20260001773751-26-000076
10-KFY202523 Feb 20260001773751-26-000022
10-KFY202326 Feb 20240001773751-24-000025
10-KFY202227 Feb 20230001773751-23-000029
8-K Ex 99.1/99.2Q4 202523 Feb 20260001773751-26-000019
DEF 14A202628 Apr 20260001773751-26-000060
Table A.2 Further filings used: Hims & Hers Forms 8-K and peer filings
CompanyFormFiledAccession number
Hims & Hers10-K FY202424 Feb 20250001773751-25-000062
Hims & Hers8-K Ex 99.2, Q4 2024 letter24 Feb 20250001773751-25-000059
Hims & Hers8-K (Items 8.01)17 Nov 20250001773751-25-000362
Hims & Hers8-K (Items 1.01, 3.02, 7.01, 9.01)19 Feb 20260001773751-26-000010
Hims & Hers8-K (Items 7.01, 9.01)11 Mar 20260001773751-26-000033
Hims & Hers8-K (Items 2.02, 9.01)11 May 20260001773751-26-000074
Hims & Hers8-K (Items 8.01, 9.01)19 May 20260001193125-26-229749
Hims & Hers8-K (Items 1.01, 2.03, 3.02, 9.01)21 May 20260001193125-26-234847
Hims & Hers8-K (Items 1.01, 2.03, 8.01, 9.01)2 Jun 20260001773751-26-000091
Hims & Hers8-K (Items 5.07)15 Jun 20260001773751-26-000096
Hims & Hers8-K (Items 1.01, 2.03, 9.01)1 Jul 20260001773751-26-000146
Hims & Hers8-K (Items 5.02)17 Jul 20260001773751-26-000149
Hims & Hers8-K (Items 2.02, 9.01)10 Aug 20260001773751-26-000161
Hims & Hers8-K (Items 5.02)7 Oct 20260001773751-26-000220
Eli Lilly10-Q Q3 202629 Oct 20260000059478-26-000108
Eli Lilly8-K29 Oct 20260000059478-26-000104
GoodRx8-K Item 4.022 Nov 20260001809519-26-000184
LifeMD10-Q5 Aug 20260001493152-26-036200
Novo Nordisk6-K4 Nov 20260001628280-26-069805
Teladoc Health10-Q29 Oct 20260001477449-26-000052
WW International10-Q5 Nov 20260001193125-26-448563
Table B.1 Exhibits to Forms 8-K filed in the last twelve months
FiledExhibitDocumentContent
19 Feb 2026EX-2.1Securities Sale Deed for Eucalyptus (EUC Management Pty Ltd)Purchaser Horizon BidCo Pty Ltd; guarantor Hims, Inc.; deed dated 19 Feb 2026 (summarised from 8-K Item 1.01); Consideration up to about $1.15bn: about $240m upfront, about $710m deferred, up to about $200m earn outs
19 Feb 2026EX-99.1Press release: agreement to acquire EucalyptusEucalyptus operates in Australia, UK, Germany, Japan and Canada; brands Juniper and Pilot; more than 775,000 customers; Annual revenue run rate above $450m (non GAAP, January 2026 gross fulfilled billings annualised); triple digit ARR growth each quarter of 2025
23 Feb 2026EX-99.1Q4 and FY2025 results press releaseQ4 2025 revenue $617.8m (+28%); FY2025 revenue $2.35bn (+59%); FY2025 net income $128.4m; Adj. EBITDA $318.0m vs $176.9m; FCF $57.4m vs $198.3m
23 Feb 2026EX-99.2Q4 2025 shareholder letterWeight Loss, Men's Dermatology, Sexual Health and Women's Dermatology each above $100m annual revenue; Hers approaching $1bn; Hims revenue grew more than 30% and Hers more than 100% in 2025; majority of 2025 revenue from non GLP‑1 offerings
11 Mar 2026EX-99.1Strategic shift for US weight loss; Novo Nordisk collaboration (release dated 9 Mar 2026)US weight loss to focus on FDA approved GLP‑1s; compounded semaglutide offered on a limited scale when clinically necessary; No further advertising of compounded GLP‑1 offerings
11 May 2026EX-99.1Q1 2026 results press releaseRevenue $608.1m (+4%); US $529.9m (-8%); Rest of World $78.2m (+969%); Gross margin 65% vs 73%; net loss $92.1m; Adj. EBITDA $44.3m vs $91.1m
19 May 2026EX-99.1Press release: proposed $300m convertible notes offering due 2032Proposed private offering of $300m convertible senior notes due 2032 under Rule 144A; Proceeds for international expansion including Eucalyptus, technology and capped calls
19 May 2026EX-99.2Press release: pricing of upsized $350m 0% convertible notes due 2032Upsized to $350m from $300m, plus $52.5m option; 0% coupon, maturity 1 Jun 2032; Conversion price about $29.53, 32.5% premium to $22.29 close on 18 May 2026
21 May 2026EX-4.1Indenture for 0% Convertible Senior Notes due 2032 (US Bank Trust Company, trustee)$402.5m principal issued 21 May 2026 (option exercised in full); Initial conversion rate 33.8590 shares per $1,000 (about $29.53)
21 May 2026EX-10.1 / EX-10.2Forms of base and additional capped call confirmationsCounterparties HSBC, Barclays, BNP Paribas, Truist and Morgan Stanley; Cap price about $50.15 (125% premium to 18 May 2026 price)
2 Jun 2026EX-10.1Amendment No. 3 to Revolving Credit and Guaranty Agreement (29 May 2026)Facilitates Eucalyptus closing with grace period for covenant and representation compliance; Adds joinder obligations for material foreign subsidiaries
2 Jun 2026EX-99.1Press release: completion of Eucalyptus acquisitionClosed (1 Jun 2026); presence across US, UK, Australia, Canada; growing in France, Germany, Ireland, Spain, Japan; Eucalyptus has served more than 850,000 customers (as of May 2026)
1 Jul 2026EX-10.1Master Receivables Purchase Agreement with JPMorgan Chase (1 Jul 2026)Sellers XeCare LLC and Apostrophe Pharmacy LLC; $400m facility limit; purchaser may decline any offer; Initial term 364 days, extendable by agreement
1 Jul 2026EX-10.2Amendment No. 4 to Revolving Credit Agreement (26 Jun 2026)Permits the RPA and performance undertaking; New permitted debt basket of up to $400m for the RPA
10 Aug 2026EX-99.1Q2 2026 results press releaseRevenue $753.2m (+38%); US $621.8m (+16%); Rest of World $131.4m (+1,641%); Gross margin 64% vs 76%; net loss $86.3m; Adj. EBITDA $60.3m vs $82.2m
9 Nov 2026EX-99.1Q3 2026 results press releaseRevenue $890.4m (+49%); US $657.1m (+21%); Rest of World $233.3m (+321%); Gross margin 57% vs 74%; net loss $33.0m vs net income $15.8m
9 Nov 2026EX-10.2 (10-Q)Amendment No. 5 to Revolving Credit and Guaranty Agreement (25 Aug 2026)Adds clause (e) to Excluded Subsidiary: subsidiaries on Schedule 1.1(b) excluded from guarantee requirements even if Material Foreign Subsidiary; Exclusion ends once a listed subsidiary's trailing four quarter gross revenue reaches 5% of consolidated gross revenue
9 Nov 2026EX-10.3 (10-Q)Amending Deed No.2 to Eucalyptus Securities Sale Deed (29 Sep 2026)Parties H&H Australia Intermediate Holdings and Shareholder Representative Services LLC; Deletes 'the first Business Day of the calendar month immediately following' from clause 4.2(b), changing payment timing